RedHill Biopharma (RDHL) Cash from Investing Activities (2012 - 2022)
RedHill Biopharma (RDHL) posted quarterly Cash from Investing Activities of -$163000.0 for Q2 2022, up 95.35% year-over-year from -$83441.3 in Q2 2021, and up 95.35% quarter-over-quarter from -$3.5 million in Q2 2021.
RedHill Biopharma (RDHL) Cash from Investing Activities (2012 - 2022) Analysis & Trends
RedHill Biopharma (RDHL) has reported Cash from Investing Activities for 11 consecutive years, with -$163000.0 the latest figure, recorded in Q2 2022.
- In Q2 2022, Cash from Investing Activities rose 95.35% year-over-year to -$163000.0; the TTM figure through Jun 2022 stood at -$56.9 million (down 13.18% YoY), while the FY2025 annual figure was -$5000.0, up 44.44% from the prior year.
- Cash from Investing Activities improved to -$163000.0 in Q2 2022 per RDHL's latest filing, from -$3.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $6.5 million in Q2 2018 and bottomed at -$49.8 million in Q2 2020.
- Historically, Cash from Investing Activities has averaged -$10.1 million across 5 years, with a median of -$3.4 million in 2019.
- Annual changes were most pronounced in 2018 — Cash from Investing Activities jumped 232.54% — and 2020, when it sank 1368.88%.
- RedHill Biopharma's Cash from Investing Activities stood at $6.5 million in 2018, then tumbled by 152.51% to -$3.4 million in 2019, then tumbled by 1368.88% to -$49.8 million in 2020, then soared by 92.97% to -$3.5 million in 2021, then jumped by 95.35% to -$163000.0 in 2022.
- Business Quant data shows RDHL's Cash from Investing Activities at -$163000.0 in Q2 2022, -$3.5 million in Q2 2021, and -$49.8 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -163,000.00 |
| Jun 30, 2022 | -163,000.00 |
| Jun 30, 2021 | -3.50 Mn |
| Jun 30, 2021 | -3.50 Mn |
| Jun 30, 2020 | -49.80 Mn |
| Jun 30, 2020 | -49.80 Mn |
| Jun 30, 2019 | -3.39 Mn |
| Jun 30, 2019 | -3.39 Mn |
| Jun 30, 2018 | 6.46 Mn |
| Jun 30, 2018 | 6.46 Mn |
| Jun 30, 2017 | -4.87 Mn |
| Jun 30, 2017 | -4.87 Mn |
| Mar 31, 2017 | -18.60 Mn |
| Mar 31, 2017 | -18.60 Mn |
| Jun 30, 2016 | -2.92 Mn |
| Jun 30, 2016 | -2.92 Mn |
| Mar 31, 2016 | -4.60 Mn |
| Mar 31, 2016 | -4.60 Mn |
| Mar 31, 2015 | -7.08 Mn |
| Mar 31, 2015 | -7.08 Mn |